Ann: ACW randomizes first US participant in Alzheimers trial, page-17

Our cash burn with two trials running is around $5m per qtr. That’s not unusual. With only one trial it’s closer to $3-4m per qtr depending on the stage of trial. Again this is industry standard for a company like ACW and the type and size of trials we’re running.

Our only means of raising capital, other than our tax rebate, is on-market by way of placement to new or existing holders. And we can’t just raise unlimited capital at any price or time that suits. It’s going to happen on a regular basis as needed until we secure a partner or have the drug on market. And just because the price spiked up to 9c before the depression results doesn’t mean that we could have got a decent capital raising away on short notice without significant dilution that would have hammered the shareprice and again given you more reason to criticise the company.

So instead of pissing and moaning on a constant basis, why don’t you tell us all what your genius strategy is to manage capital without dilution and complete the trials without an industry standard cash burn.